Buy MYNZ by Mar 30, 2026.

Recent priority reviews remind everyone that time to decision is a pricing lever. When the path and dates are clear, burn drops, partners lean in, and the market pays a higher multiple for the same asset. For screening, the U.S. already reimburses approved noninvasive CRC tests every three years. The gate for MYNZ is execution, not a new code. Clinically, pooled next gen ColoAlert performance is about 92% CRC sensitivity, 82% advanced adenomas, and 95.8% high grade dysplasia. The need …